What is Physulime used for?

Physulime is indicated for Paraneoplastic hyponatremia.

Physulime is developed by Otsuka Pharmaceutical Co., Ltd..

What development phase is Physulime in?

Physulime is FDA-approved (marketed).

What is the generic name of Physulime?

MOZAVAPTAN is the generic (nonproprietary) name of Physulime.

Last reviewed 2026-04-20 · How we verify

Physulime (MOZAVAPTAN)

Otsuka Pharmaceutical Co., Ltd. · FDA-approved approved Small molecule Quality 24/100

At a glance

Generic name	MOZAVAPTAN
Sponsor	Otsuka Pharmaceutical Co., Ltd.
Drug class	mozavaptan
Target	Vasopressin V2 receptor
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved
First approval	2006

Approved indications

Paraneoplastic hyponatremia

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Physulime CI brief — competitive landscape report
Physulime updates RSS · CI watch RSS
Otsuka Pharmaceutical Co., Ltd. portfolio CI